Important note
This AI stock analysis for Astrazeneca is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!
Astrazeneca - AI Stock Analysis
Analysis generated November 14, 2024
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company operates in three main therapeutic areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), and Respiratory. With a diverse portfolio and a strong pipeline of new drugs, AstraZeneca has positioned itself as a leader in the pharmaceutical industry.
Fundamental Analysis
AstraZeneca's revenue for the last quarter was $12.9 billion, which is consistent with the previous quarter, indicating stability. However, when compared to the same quarter last year, the revenue has increased by 13.33%, signifying positive year-over-year growth.
Similarly, net income for the last quarter was $1.93 billion, also matching the previous quarter and showing stability. Compared to the same quarter last year, net income has risen by 6.00%, suggesting positive year-over-year growth.
The EBITDA for the last quarter was $4.12 billion, consistent with the previous quarter. However, it has shown a remarkable increase of 63.52% compared to the same quarter last year, indicating substantial improvement in operational efficiency and profitability.
The current Price-to-Earnings (P/E) ratio stands at 31.65. This is relatively high and may indicate potential overvaluation, prompting a bearish outlook from some investors.
Technical Analysis
AstraZeneca’s stock price today is $65.29. This represents a decrease of 16.40% from a month ago, which could be concerning in the short term. However, compared to a year ago, there is an increase of 5.66%, suggesting a positive long-term trend despite the recent downturn.
The stock trend is currently bearish. The current 10-day Simple Moving Average (SMA10) is $64.88, which is lower than the previous SMA10 of $65.50. This implies a potential downward trend in price movement.
The Relative Strength Index (RSI) is 59.1, indicating a neutral condition. The RSI score shows that the stock is neither overbought nor oversold at this moment, suggesting a balanced demand and supply in the market.
Alternative Data Analysis
Looking at job postings and employee sentiment, AstraZeneca has 1,189 open positions, which is up by 8% in the last few months. This increase suggests that the company is looking to grow and expand, potentially a positive sign of health and activity within the organization.
In terms of customer acquisition, AstraZeneca has an approximated 960,000 visitors to their webpage. This number is up by 21% in the last few months, which is a bullish trend as it may lead to increased customer engagement and sales.
On social media, AstraZeneca’s Instagram page boasts 78,000 followers, growing by 4% in the last couple of months, showing increasing public interest. However, their Twitter following has stagnated at 300,000 followers with no recent growth, which could indicate a plateau in interest on that platform.
According to AltIndex’s AI score, which predicts a company’s stock price based on fundamental, technical, and alternative data analyses, AstraZeneca has a score of 72. This is a buy signal, suggesting positive expectations for the stock.
Conclusion and Recommendation
In conclusion, AstraZeneca demonstrates stable financial performance and healthy year-over-year growth in revenue, net income, and EBITDA. Despite the high P/E ratio potentially indicating overvaluation, the company shows strong operational efficiency and a robust growth trajectory.
The recent decline in stock price and bearish trend might be a short-term concern, but the long-term trend remains positive. The neutral RSI and current SMA10 values provide a balanced view of current market conditions. Additionally, the alternative data indicates company expansion, increased customer acquisition, and solid interest on social media platforms.
Considering all the data, including the AI score from AltIndex, which provides a buy signal at 72, the recommendation would be to take a cautious but optimistic position on AstraZeneca. It would be wise to consider buying the stock, especially if the short-term price weakness is seen as an entry point for long-term gains.
Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.
